As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

As­traZeneca’s on­col­o­gy R&D group un­der José Basel­ga keeps churn­ing out hits.

Wednes­day morn­ing the phar­ma gi­ant and their part­ners at Mer­ck part­ed the cur­tains on a suc­cess­ful read­out for their Phase III PAO­LA-1 study, demon­strat­ing sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in pro­gres­sion-free sur­vival for women with ovar­i­an can­cer in a first-line main­te­nance set­ting who added their PARP Lyn­parza to Avastin. This is their sec­ond late-stage suc­cess in ovar­i­an can­cer, which will help stave off ri­vals like GSK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER